EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis

Einas M Yousef iD, Motaz Talaat Elghnam iD, Hiba Elhassan, Malak Hassan iD, Saifeldin Yousef, Hend Aabed iD, Noha Mitwally iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177719 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Einas M Yousef und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy & Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Breast Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alfaisal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in systemic therapy, many early breast cancer patients experience recurrence due to subclinical minimal residual disease (MRD). Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have emerged as promising liquid biopsy markers for post-treatment MRD detection. This pre-registered systematic review and meta-analysis (PROSPERO/PRISMA 2020) evaluated their comparative prognostic significance. Seven databases were searched from inception to March 2026. Eligible studies included early breast cancer patients undergoing post-treatment ctDNA or CTC assessment after neoadjuvant or adjuvant therapy, reporting survival outcomes with extractable hazard ratios. Quality was assessed using the QUIPS tool; random-effects meta-analyses used the REML estimator. Seventeen studies (thirteen ctDNA, four CTCs; n = 3030) were included. Post-treatment CTC positivity was significantly associated with poorer survival (pooled HR = 2.99, 95% CI: 1.99–4.49; I2 = 17.2%). ctDNA positivity demonstrated a substantially stronger prognostic effect (pooled HR = 10.28, 95% CI: 6.32–16.70; I2 = 47.3%). Subgroup analyses identified assessment timing as a key heterogeneity source, with stronger effects after adjuvant (HR = 20.62; k = 4) versus neoadjuvant therapy (HR = 6.07; k = 9); given the small number of post-adjuvant studies, this finding is hypothesis-generating. No significant publication bias was detected. Both markers were significant prognostic markers of MRD. ctDNA showed a stronger pooled prognostic association, although no study assessed both biomarkers within the same cohort and direct head-to-head comparisons therefore remain lacking. Prospective randomized trials are needed to evaluate MRD-guided treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingBreast NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemalePrognosisLiquid BiopsyNeoplasm, Residual

Stichwörter der Autor:innen

circulating tumor DNAcirculating tumor cellsearly breast cancerliquid biopsymeta-analysisminimal residual diseaseprognostic biomarkersystematic review

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Anatomy & Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Anatomy and Embryology Department, Faculty of Medicine, Cairo University, Cairo 11956, Egypt.
  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Faculty of Medicine, Badr University in Cairo, Cairo 11829, Egypt.
  • Department of Anatomic Pathology, Cairo University Hospitals, Cairo 11956, Egypt.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

ORCID-Profile: Einas M Yousef, Motaz Talaat Elghnam, Malak Hassan, Hend Aabed, Noha Mitwally

Förderung

  • Alfaisal University

Zitieren

APA

Yousef, E. M., Elghnam, M. T., Elhassan, H., Hassan, M., Yousef, S., Aabed, H., & Mitwally, N. (2026). Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177719

Vancouver

Yousef EM, Elghnam MT, Elhassan H, Hassan M, Yousef S, Aabed H, et al. Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177719

BibTeX
@article{Yousef2026,
  author = {Yousef, Einas M and Elghnam, Motaz Talaat and Elhassan, Hiba and Hassan, Malak and Yousef, Saifeldin and Aabed, Hend and Mitwally, Noha},
  title = {Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177719}
}
Kostenlos starten →